ImmuneOnco Biopharmaceuticals (Shanghai) Applies for Phase III Clinical Trial Approval of IMM0306 for Follicular Lymphoma in China (Note: There is no indication of grant/funding or involvement of multiple organizations in the provided announcement; the news is about a regulatory application for a Phase III clinical trial.)
**ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. Submits Phase III Clinical Trial Application for IMM0306 in Follicular Lymphoma** ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced that it has submitted an application to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for a Phase III clinical trial of its investigational therapy, IMM0306, for the treatment of follicular lymphoma. IMM0306 is a first-in-class bispecific molecule targeting both CD47 and CD20, designed to enhance immune-mediated elimination of malignant B cells while minimizing toxicity. The company currently retains global intellectual property and commercial rights to IMM0306. No grant or funding from other organizations was mentioned in the announcement. The company cautioned that there is no guarantee of successful development or commercialization of the drug.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。